The drugs market in recent years is more inclined towards developing molecules focused on target based therapies such as biologics, personalized medicines and biosimilars. Target based therapies are predominantly required for treating chronic diseases and orphan conditions, hence the development of the suitable medication should be expedited. The successful example of personalized medicine is approval of the product kalydeco (ivacaftor) for treating cystic fibrosis patients with a specific gene mutation (G551D). Target based therapies are patient centric and require genetic studies to be carried out. Cell cultures are the fundamental requirement for carrying out these gene based studies. Cell culture processes are time consuming and require utmost monitoring to avoid contamination and to acquire appropriate growth of predetermined cells for further analysis and studies. Manual monitoring of cell cultures are widely followed across industries and research institutes which comprises periodic sample testing. This process increases the risk of contamination and thus accounts for loss of cell sample, time and money.

Cell culture monitoring biosensors are analytical devices that comprise a biological component fused with a physicochemical component for the analysis of a suitable metabolite of predetermined importance. The biosensors comprise a suitable electrode on which a corresponding sensing element is immobilized. The desired analyte reacts with the sensing element and activates the electrode. Cell culture monitoring biosensors detect various activities occurring during the process of cell culture. Change in temperature, release of desired metabolites, release of toxic substance and the occurrence of cell growth and rise in cell density can be monitored using suitable biosensors. Manual monitoring of the aforementioned changes in cell culturing could lead to errors and risk for contamination thus slowing down the entire process. Such errors could have a negative impact on drug development. Cell culture errors could also hamper the scaling up process in case of biosimilar development and vaccine development.

Perpetual rise in the progress of biologics, biosimilars and personalized medicines and the need for hastened development of the same fuel the demand for cell culture monitoring biosensors in present and forecast period, 2017-2025.

Biologics, biosimilars and personalized medicine are slowly gaining global presence thus propelling the demand for cell culture monitoring biosensors. Among all the geographies across, North America comprehends major developments in target based therapies thus encapsulating a major stake in the cell culture monitoring biosensors market. Europe also holds a strong position in the cell culture monitoring biosensors market owing to rise in biologics and biosimilar development along with presence of key biosensors industries in this region, thus catapult the demand for cell culture monitoring biosensors. Asia Pacific is expected to attain a steady growth pertaining to cell culture monitoring biosensors market in the forecast period, 2017-2025. The growth is attributed to the adoption of newer technologies and the rise in healthcare expenditure fuelling R&D activities.

Market Competition Assessment:

The cell culture monitoring biosensors market is dominated by few players thus creating opportunities for the emerging players in this market. Lifeonics is one of the key players in this market with its advanced technology ‘SMOD’. This device is enabled with Bluetooth connectivity providing remote monitoring of the cell cultures pertaining to temperature changes and cell density details. The other existing key players are C-CIT Sensors AG, Lonza, Nova Biomedical, Nanomedical Diagnostics, Sarissa Biomedical Ltd., Conductive Technologies Inc., Sierra Sensors GmbH and VacciXcell.